Migraine is a debilitating neurological condition that involves the neuropeptide calcitonin
gene-related peptide (CGRP). An exciting development is the recent FDA approval of the …

Migraine is a highly prevalent headache disease that typically affects patients during their
most productive years. Despite significant progress in understanding the underlying …

Calcitonin gene-related peptide (CGRP), a neuropeptide abundant in the trigeminal system
and widely expressed in both the peripheral and central nervous systems, has recently …

Migraine is a highly prevalent, complex neurological disorder. The burden of disease and
the direct/indirect annual costs are enormous. Thus far, treatment options have been …

Calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide found mostly in
peptidergic sensory C-fibers, has been suggested to be implicated in the pathogenesis of …

Migraine is the most prevalent neurological disorder worldwide and it has immense
socioeconomic impact. Currently, preventative treatment options for migraine include drugs …

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however,
many patients with migraine do not benefit from drugs that antagonize the CGRPergic …

The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine
pathophysiology has led to advances in the treatment of migraine. Since 2018, the Food and …

Migraine is a common neurologic disorder characterized by attacks consisting of unilateral,
throbbing headache accompanied by photophobia, phonophobia, and nausea which …

Migraine is a highly prevalent, severe, and disabling neurological condition with a significant
unmet need for effective acute therapies. Patients (~ 50%) are dissatisfied with their currently …